Press Releases Year None2024202320222021202020192018 Nov 15, 2024 Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 Nov 13, 2024 Akero Therapeutics to Present at the Jefferies London Healthcare Conference Nov 08, 2024 Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Oct 21, 2024 Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 Sep 30, 2024 Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference Sep 09, 2024 Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH Aug 28, 2024 Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference Aug 09, 2024 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Jun 11, 2024 Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH Jun 08, 2024 Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
Year None2024202320222021202020192018 Nov 15, 2024 Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 Nov 13, 2024 Akero Therapeutics to Present at the Jefferies London Healthcare Conference Nov 08, 2024 Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Oct 21, 2024 Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 Sep 30, 2024 Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference Sep 09, 2024 Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH Aug 28, 2024 Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference Aug 09, 2024 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Jun 11, 2024 Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH Jun 08, 2024 Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
Nov 15, 2024 Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
Nov 08, 2024 Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 21, 2024 Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
Sep 09, 2024 Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
Aug 28, 2024 Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 09, 2024 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Jun 11, 2024 Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
Jun 08, 2024 Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
